Sign in Subscribe
Genetic research

Gene Therapy Breakthrough in Heart Transplants

Strategic Insights

— 1 min read

Research at Duke University Medical Center has made significant advancements in the field of gene therapy, providing new hope for heart transplant patients. Scientists have developed a method of delivering a muscle-tropic recombinant adeno-associated virus (AAV) to donor hearts during normothermic ex-vivo organ perfusion (EVP) systems. This approach has shown promising results, with durable cardiac transgene expression lasting up to 90 and 120 days post-transplant in a porcine preclinical model. The study's findings suggest that this technique could be a critical foundation for future translational studies aimed at improving heart transplant outcomes.

Key Takeaways:

  • Researchers at Duke University Medical Center have developed a novel gene therapy approach using a muscle-tropic AAV to deliver therapeutic transgenes to donor hearts during EVP systems.
  • The study demonstrated durable cardiac transgene expression lasting up to 90 and 120 days post-transplant in a porcine preclinical model.
  • The technique showed no functional or structural impact on the allograft and no off-target gene expression in the recipient.
  • The research aims to inform translational studies with therapeutic transgenes to improve allo-, xeno-, and auto-heart transplant outcomes.
  • The study's outcome may potentially improve heart transplant success rates and patient survival.
  • AAV-SLB101, a recombinant AAV, was used in the study, and its safety and efficacy were demonstrated.

Statistics:

  • Up to 90 and 120 days post-transplant, durable cardiac transgene expression was achieved in a porcine preclinical model.
  • The study demonstrated that the AAV-SLB101 approach was efficient, durable, and safe in a preclinical porcine heart transplant model.
  • The study's findings may lead to improved heart transplant outcomes, potentially reducing mortality rates and improving patient quality of life.
  • The research highlights the innovative use of EVP systems in gene therapy, providing new avenues for therapeutic strategies.

Sources:

  • NewsRx. Studies from Duke University Medical Center Update Current Data on Gene Therapy (Delivery of a Muscle-Targeted Adeno-Associated Vector Via Ex Vivo Normothermic Perfusion Is Efficient, Durable, and Safe in a Preclinical Porcine Heart Transplant ...). Cardiovascular Week. June 16, 2025; p 119.
  • https://doi-org.sdpl.idm.oclc.org/10.3389/ti.2025.13971 (Free access to the journal article via Frontiers Media S.A.)

Read more